ABCDEFGHIJKLMNOPQRSTUVWXYZAAABACADAEAFAGAHAIAJ
1
File name# of pagesKEI URLType of agreementContract numberAmendmentAwardeeGoverment agencyShort descriptionDate signedAmendment DatesAmountMarch-inPractical applicationGov't use of patented inventionsGov't rights to dataPatent ownershipReporting on utilization of subject inventionsNotes
2
BARDA_Genentech_OTA_Modification_HHSO100201800036C_2020.Mar.27.pdf26https://drive.google.com/file/d/1uVfrOrIBul1hsq482tvBYmE6mpO8P50z/view?usp=sharingOTAHHSO100201800036C
Modification of 27Sept2018
Genentech (Roche)BARDAUmbrella AgreementMarch 27,2020not listed/redactednot listed/redacted
not listed/redacted
not listed/redacted
not listed/redacted
not listed/redactedLargely redacted
3
BARDA_Genentech_OTA_OriginalPart1_HHSO100201800036C_2018.Sep.27.pdf23https://drive.google.com/file/d/1BY2GPGqUb8Ol5QKJX3-nCJx3JwUG0C7q/view?usp=sharingOTAHHSO100201800036COriginalGenentech (Roche)BARDAUmbrella AgreementSeptember 27, 2018page 27page 7page 23page 20page 27
For clarity, this license does not include the right to use or allow others to use the Subject Invention for commercial purposes.
4
BARDA_J&J_OTA_HHSO100201800012C_2018.Sep.21.pdf115https://drive.google.com/file/d/1GW4AX6_nqLwu96P5KJPoNe6bQdbltjy6/view?usp=sharingOTAHHSO100201800012COriginalJanssen (J&J)BARDARedactedSeptember 21, 2018September 21, 2018-December 31, 2024page 26page 25N/Apage 27page 25
5
BARDA_J&J_OTA_HHSO100201800012C_Amendment4_2020.Feb.14.pdf36https://drive.google.com/file/d/1VI_VNxGv3WaonzI025K7j2hAgqwTBXes/view?usp=sharingOTAHHSO100201800012CAmendment 4Janssen (J&J)BARDARedactedFeb 14, 2020May 1, 2020-March 31, 2021not listed/redactednot listed/redacted
not listed/redacted
not listed/redacted
page 6not listed/redacted
6
BARDA_J&J_OTA_HHSO100201700018C_Amendment6_2020.Feb.11.pdf18https://drive.google.com/file/d/1o6TAnrItfjO7nT2OtS6ir5imISXJJC_G/view?usp=sharingOTAHHSO100201700018CAmendment No. 0006Janssen (J&J)BARDA
Influenza Portfolio and Other Emerging Pathogens Development Candidates
February 11, 2020not listed/redactednot listed/redacted
not listed/redacted
not listed/redacted
page 6not listed/redacted
7
BARDA_J&J_OTA_HHSO100201700018C_Amendment7_2020.Mar.20.pdf21https://drive.google.com/file/d/1zNK-QbGtRKDrXtwIm-jePSs7RAQtzLut/view?usp=sharingOTAHHSO100201700018CAmendment No. 0007Janssen (J&J)BARDA
Influenza Portfolio and Other Emerging Pathogens Development Candidates
March 20, 2020April 30, 2023-December 31, 2024not listed/redactednot listed/redacted
not listed/redacted
not listed/redacted
not listed/redacted
not listed/redacted
8
BARDA_J&J_OTA_HHSO100201700018C_Amendment8_2020.Mar.27.pdf29https://drive.google.com/file/d/1Vb5-cndCqq45VfyGHghFiIOK_Y1Aw3hx/view?usp=sharingOTAHHSO100201700018CAmendment No. 0008Janssen (J&J)BARDA
Influenza Portfolio and Other Emerging Pathogens Development Candidates
March 27, 2020see notesnot listed/redactednot listed/redacted
not listed/redacted
not listed/redacted
page 6 & 8not listed/redacted
Page 1: "Total Amount of the Agreement is increased by REDACTED for addition COVID REDACTED cost share adjustment from $715,837,436 to REDACTED includes Recipient and Government Funding)." Page 2: "...the total Funds Obligated is increased by $456,237,081 from $233,288,786 to $689,525,867."
9
BARDA_ModernaTX_Contract_75A50120C00034_2020.Apr.16.pdf112https://drive.google.com/file/d/1fS3LhRnVpEb8MokpWFmsDIrD2qjvvPTd/view?usp=sharingBayh-Dole & FAR Standard75A50120C00054OriginalModerna (ModernaTX)BARDAApril 16, 2020$430,298,520.00p 50, FAR 52.277-11p 50, FAR 52.277-11
p 50, FAR 52.277-11
10
BARDA_Protein Sciences Corp_Contract_HHSO100201600005I_2020.Feb.14.pdf24https://drive.google.com/file/d/16QJnBt6SCKFB83YDuCdG16TqLGTjtQbU/view?usp=sharingHHSO100201600005IProtein SciencesBARDAFebruary 14, 2020not listednot listedsee notes
PSC understands that the USG shall grant an irrevocable worldwidenon-exclusive sublicensable royalty-free license to use for any purpose any and all improvements and intellectual property that result from the USG or USG's collaborator's use of the material provided herunder by pSC and affiliates to the USG.
11
BARDA_Regeneron_OTA_HHSO100201700020C_2020.Jan.31.pdf71https://drive.google.com/file/d/18IFvXXDsML0mP4GQLmMgdtUtjGUTwHQm/view?usp=sharingOTAHHSO100201700020CRegeneron PharmaceuticalBARDAJanuary 31, 20207 (18 of document)24 (35 of doc)21 (32 of doc)page 26
12
DOD_Ology_OTA_W911QY2090003_2020.Feb.21.pdf33https://drive.google.com/file/d/1LEjEsgA-sCQmWAoXzO4Kl22rnFVvTkSW/view?usp=sharingOTA (10 U.S.C. § 2373 Agreement)W911QY2090003Ology BioservicesDoD (Natick)February 21, 2020not listednot listedpage 13page 12
This Agreement is not subject to the Bayh-Dole Act, 35 U.S.C. §§ 200-212.
13
DOD_Ology_OTA_W911QY2090003_Appendix A-4_2020.March.22.pdf15https://drive.google.com/file/d/1ZD8Q3VqmHgboQ_AUhpV_F4I7hu3jtrSi/view?usp=sharingOTA (10 U.S.C. § 2373 Agreement)W911QY2090003Ology BioservicesDoDStatement of Work (SOW)March 22, 2020not listednot listednot listed
page 15 (re: lack thereof)
not listednot listed
Inovio will disclose its background intellectual property that is relevant to this Agreement Separately in a Cooperative Research and Development Agreement between the Government and Inovio.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100